The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.
Lars Bastholt
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Marcia S. Brose
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Research Funding - Bayer
Barbara Jarzab
Honoraria - Bayer
Martin Schlumberger
Consultant or Advisory Role - AstraZeneca; Bayer; Eisai; Genzyme
Honoraria - AstraZeneca; Bayer; Eisai; Genzyme
Research Funding - AstraZeneca; Bayer; Eisai; Genzyme
Salvatore Siena
No relevant relationships to disclose
Christelle De La Fouchardiere
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Ralf Paschke
Other Remuneration - Bayer
Hari Anant Deshpande
Consultant or Advisory Role - Bayer
Yuankai Shi
No relevant relationships to disclose
Rossella Elisei
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Ming Gao
No relevant relationships to disclose
Lin Li
No relevant relationships to disclose
Klaas Prins
Consultant or Advisory Role - Bayer
Helen Walker
Consultant or Advisory Role - Bayer
David Y. Mitchell
Consultant or Advisory Role - Bayer
John T. Lettieri
Employment or Leadership Position - Bayer
Istvan Molnar
Employment or Leadership Position - Bayer
Christian Kappeler
Employment or Leadership Position - Bayer
Carol Elaine Pena
Employment or Leadership Position - Bayer